NCT02782975View on ClinicalTrials.gov

Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions
Alzheimer's Disease
Interventions
DRUG

aducanumab

Trial Locations (2)

47710

Research Site, Evansville

75247

Research Site, Dallas

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY

NCT02782975 - Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants | Biotech Hunter | Biotech Hunter